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Abstract
Background: δ-storage pool disease (δ-SPD) is a bleeding disorder characterized by a 
reduced number of platelet-dense granules. The diagnosis of δ-SPD depends on the 
measurement of platelet ADP content, but this test is time consuming and requires a 
relatively large blood volume. Flow cytometric analysis of platelet mepacrine uptake 
is a potential alternative, but this approach lacks validation, which precludes its use 
in a diagnostic setting.
Objectives: To evaluate the performance of platelet mepacrine uptake as a diagnostic 
test for δ-SPD.
Patients/Methods: Mepacrine fluorescence was determined with flow cytometry be-
fore and after platelet activation in 156 patients with a suspected platelet function 
disorder and compared with platelet ADP content as a reference test. Performance 
was analyzed with a receiver operating characteristic (ROC) curve.
Results: Eleven of 156 patients had δ-SPD based on platelet ADP content. Mepacrine 
fluorescence was inferior to platelet ADP content in identifying patients with δ-SPD, 
but both mepacrine uptake (area under the ROC curve [AUC] 0.87) and mepacrine 
release after platelet activation (AUC 0.80) had good discriminative ability. In our 
tertiary reference center, mepacrine uptake showed high negative predicitive value 
(97%) with low positive predictive value (35%). Combined with a negative likelihood 
ratio of 0.1, these data indicate that mepacrine uptake can be used to exclude δ-SPD 
in patients with a bleeding tendency.
Conclusion: Mepacrine fluorescence can be used as a screening tool to exclude δ-SPD 
in a large number of patients with a suspected platelet function disorder.
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1  | INTRODUC TION
Platelets play an important role in hemostasis by forming a platelet 
plug upon vascular injury. When platelets are activated, they secrete 
the content of their storage organelles, alpha- and dense granules, 
to promote further platelet activation and coagulation.1,2 One of the 
molecules secreted from dense granules is ADP, which promotes 
secondary platelet activation via the P2Y12 receptor and is essential 
for thrombus stability.3
Defects in platelet-dense granules can be classified into stor-
age pool disease (δ-SPD) and secretion defects. δ-SPD results from 
either a decreased number or complete absence of dense granules 
or a decreased granule content, such as the empty sack syndrome.4 
Secretion defects are associated with a defective release mechanism 
resulting from impaired signal transduction or granule trafficking.5
Platelet secretion disorders, in particular dense granule disor-
ders, are the most common inherited platelet function disorders and 
may be more prevalent than von Willebrand disease.6 Nonetheless, 
there is no consensus on the best laboratory practice to detect these 
disorders, and the methodology is poorly standardized.7,8 The cur-
rent approach to evaluate platelet-dense granule secretion includes 
lumi-aggregometry and the measurement of ADP and ATP in platelet 
lysate using bioluminescence.9,10 Lumi-aggregometry is currently the 
most often used method, but cannot distinguish between a decreased 
granule number or a secretion defect.9 Measuring ADP and ATP 
content in platelet lysates will diagnose patients with storage pool 
deficiency,11 but is insensitive for secretion defects.12 Interestingly, 
many diagnostic laboratories do not measure platelet nucleotide 
content, resulting in potential underdiagnosis of δ-SPD.13,14 In addi-
tion, none of these tests can be performed in patients with thrombo-
cytopenia. Another method used to diagnose δ-SPD is to count the 
total number of dense granules per platelet with whole mount trans-
mission electron microscopy (TEM)15,16. However, this technique is 
challenging and not widely available. Therefore, there is an unmet 
need for an easy and rapid diagnostic tool to evaluate platelet dense 
granule secretion.
Flow cytometry has been recommended by the International 
Society on Thrombosis and Haemostasis/Scientific and 
Standardization Committee guidelines as a tool to diagnose patients 
with a platelet function disorder, and has been shown to have added 
value to light transmission aggregometry in diagnosing platelet 
function disorders.9,17 Platelet granule markers, such as CD63 and 
P-selectin, have also been used in the screening of mild platelet 
function disorders on the flow cytometer, but require platelet stim-
ulation before analysis. Mepacrine, a fluorescent acridine deriva-
tive that binds adenosine nucleotides,18 has been used to measure 
platelet dense granule content. Several studies showed decreased 
platelet mepacrine fluorescence in patients with δ-SPD,19-22 and im-
plementation of mepacrine fluorescence in a diagnostic algorithm 
for platelet function disorders has been proposed.23 However, al-
though current data on mepacrine fluorescence are promising, the 
performance of mepacrine fluorescence has not yet been compared 
with routine diagnostic tests for δ-SPD in a real-life clinical set-
ting.24,25 In the present study, we validated a flow cytometric mepa-
crine fluorescence assay for dense granule content in patients with a 
suspected platelet function disorder.
2  | METHODS
2.1 | Participants
2.1.1 | Healthy volunteers
Blood from healthy individuals was obtained via the Mini Donor 
Service, a blood donation facility for research purposes that is ap-
proved by the medical ethics committee of the University Medical 
Center (UMC) Utrecht. All donors provided written informed 
consent, in accordance with the declaration of Helsinki, and self-
reported to be free from antiplatelet drugs or nonsteroidal anti-in-
flammatory drugs for at least 10 days before blood donation.
2.1.2 | Patients
Two different patient cohorts were used in this study. Cohort 1 
consisted of seven patients with a previously diagnosed δ-SPD 
(ADP content < 1.7 µmol/1011 platelets) and was used to provide 
proof of principle for diagnostic mepacrine fluorescence. Cohort 2 
included patients from the Thrombocytopathy in the Netherlands 
Heidelberglaan 100, room G03.550, 3584 
CX, Utrecht, The Netherlands.
Email: r.t.urbanus@umcutrecht.nl
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Essentials
• Flow cytometry is recommended in the diagnosistic ap-
proach of platelet function disorders.
• Prospective validation of mepacrine fluorescence for 
storage pool disease.
• High negative predictive value of mepacrine fluores-
cence in diagnosis storage pool disease.
• Mepacrine fluorescence is suitable for exclusion of stor-
age pool disease.
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(TiN) study and was used to validate the flow cytometric mepacrine 
uptake. The TiN study is a nationwide cross-sectional study to col-
lect data on clinical characteristics, functional assays, and genetics in 
a population of patients with a suspected platelet disorder. Patients 
were included when von Willebrand disease or a coagulation fac-
tor deficiency was excluded and (a) they had previously abnormal 
platelet counts or platelet function test results or (b) they exhibited a 
predominantly mucocutaneous bleeding tendency compatible with 
a platelet function disorder. After a single hospital visit, laboratory 
tests were performed for platelet count, aggregation in response to 
four agonists, nucleotide content, surface receptor expression via 
flow cytometry, and genetic analysis with a selected primary he-
mostasis gene panel. Platelet mepacrine content and release were 
measured at the time of inclusion as well. In total, the TiN cohort 
included 173 patients with a bleeding tendency in whom a platelet 
function disorder was suspected, and in 156 patients both mepacrine 
fluorescence and platelet ADP content was measured. All patients 
were aged > 18 years and were referred to the Van Creveldkliniek 
for platelet function testing. Donors and patients declared to be free 
from any antiplatelet drugs. The medical ethics review board of the 
UMC Utrecht approved this study and patients provided written in-
formed consent in accordance with the declaration of Helsinki.
2.2 | Blood collection and platelet preparation
Peripheral venous blood from patients and controls was collected 
with venipuncture into 3.2% sodium citrate Vacutainer tubes (BD 
Biosciences). Flow cytometric assays were performed in whole 
blood, whereas the other tests required platelet-rich plasma (PRP). 
PRP was obtained by centrifugation of whole blood at 160 g with-
out brake for 15 minutes at 20°C. Platelet-poor plasma was obtained 
by centrifugation of whole blood at 2000 g for 10 minutes and was 
used to adjust PRP concentration to 250 × 109 platelets/L. All exper-
iments were performed within 1 to 6 hours after blood collection.
2.3 | Flow cytometric determination of dense 
granule content
Five microliters whole blood was diluted 1:10 (v:v) in HEPES buff-
ered saline (10 mM HEPES, 150 mM NaCl, 1 mM MgSO4, 5 mM KCl, 
pH 7.4), which contained 100 µM mepacrine (Sigma Aldrich) and 
15 µg/mL in-house developed PE-conjugated anti-GP1b nanobod-
ies (clone 17), with or without 25 µM protease activating recep-
tor (PAR)-1 activating peptide SFLLRN (PAR1-AP; Bachem). Whole 
blood was incubated for 10 minutes at 37°C, after which samples 
were fixed with 0.148% formaldehyde, 137 mM NaCl, 2.7 mM KCl, 
1.12 mM NaH2PO4, 10.2 mM Na2HPO4, 1.15 mM KH2PO4, 4 mM 
EDTA, pH 6.8 for 20 minutes at room temperature and analyzed on 
a BD FACSCanto II (BD Biosciences). The flow cytometer was cali-
brated every week to maintain stable fluorescent intensity. Platelets 
were identified based on forward and sideward scatter, as well as 
GPIbα-expression. Mepacrine fluorescence was normalized on the 
median fluorescence of the healthy control population and was ex-
pressed as normalized median fluorescent intensity. The coefficient 
of variation for mepacrine uptake was 2.3%. Flow cytometric analy-
sis was reproducible within 6 hours after blood collection (data not 
shown).
2.4 | Platelet ADP concentration
One milliliter PRP with a platelet count between 100 and 250 × 
109/L was diluted 1:3 (v:v) in ice cold 86.4% ethanol, 10 mM EDTA, 
pH 7.4. Platelets were lysed by vortex and one freeze/thaw cycle 
and samples were stored at −80°C until further processing. Platelet 
lysates were split into two fractions. The first fraction was incubated 
with 95 µM phosphoenolpyruvate and 25 µg/mL pyruvate kinase in 
0.2 M Tris-Maleate, 10 mM KCl, 15 mM MgSO4, pH 7.4 at 37°C for 
15 minutes to convert all ADP to ATP. Reactions were stopped by 
heating the samples for 10 minutes at 80°C. The second fraction was 
used without prior treatment. ATP levels in both fractions were de-
termined with the ATPLite 1 step kit (Perkin Elmer) on a Spectramax 
L luminometer (Molecular Devices) according to the protocol of 
the manufacturer. ATP levels were derived from an ATP calibration 
curve. ADP concentrations were calculated by subtracting the ATP 
concentration of the second fraction from the first. ADP levels were 
expressed in µmol/1011 platelets.
2.5 | Quantification of dense granules with TEM
Platelet-dense granule numbers were counted using TEM images 
made with the Jeol1010 microscope (Jeol). Formvar-coated grids 
were stabilized with carbon (Edwards Auto306) and coated with 
100 μg/mL fibrinogen for 20 minutes at room temperature. Coated 
grids were blocked with 1% bovine serum albumin in HEPES buff-
ered saline. Platelets were allowed to adhere to the grids for 1 min-
ute, after which the grids were rinsed with demi water and air dried. 
Images of 10 platelets at 12,000× magnification were taken for every 
subject. Six independent individuals were instructed to quantify the 
dense granule number in all images according to the guidelines for 
dense granule identification.26 Observers were blinded to the case 
or control status of the sample.
2.6 | Data analysis
Statistical analysis was performed with GraphPad Prism software, 
version 6, and IBM SPSS Statistics 21. Variables were analyzed 
for a normal distribution with the Shapiro-Wilk test. Non-normally 
distributed variables were transformed with a Box-Cox power 
transformation, after which normality was checked again. Cutoff 
values for mepacrine fluorescence and mepacrine release were 
determined in normally distributed data using the 2.5th percentile 
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from 89 healthy controls. The lower cutoff value for platelet ADP 
content (<1.4 µmol/1011 platelets) was based on the 2.5th percen-
tile of 49 healthy controls. Intertest agreement between the dif-
ferent tests was expressed as Cohen's kappa coefficient. The R2 
Pearson's correlation coefficient was calculated for the correlation 
between platelet size or platelet count and mepacrine uptake. The 
discriminative ability of mepacrine fluorescence and mepacrine 
release was determined with the area under a receiver operator 
characteristic curve (AUC) in patients with a bleeding tendency 
without prior diagnosis in whom a platelet function disorder was 
suspected. Researchers were blinded for the δ-SPD diagnosis dur-
ing analysis.
3  | RESULTS
3.1 | Mepacrine fluorescence and mepacrine release 
show good agreement in patients with previously 
diagnosed with δ-SPD
Seven patients with previously diagnosed with δ-SPD were enrolled in 
this study and were compared with healthy controls. This population 
included four female and three male patients with an ADP concen-
tration ranging from 0.3 to 1.21 µmol/1011 platelets and an average 
dense granule number per platelet ranging from 0.3 to 1.15 (Table 1). 
Platelet ADP content (Figure 1A) was decreased in all patients with 
δ-SPD, whereas the platelet ATP/ADP ratio (Figure 1B) was increased 
in all patients with δ-SPD. In the seven SPD patients, platelet-dense 
granule content was also determined with flow cytometry by meas-
uring mepacrine uptake in resting platelets, or mepacrine release 
after PAR1-AP stimulation. The lower limit of normal (2.5th percen-
tile) was 75.1%. Patients with δ-SPD had reduced mepacrine uptake 
compared with healthy controls (P < .05) (Figure 1C). Platelet activa-
tion with 25 µM PAR1-AP resulted in decreased mepacrine release in 
patients with δ-SPD (Figure 1D). Mepacrine uptake did not correlate 
with platelet size (R2 = 0.02; P = .43) or platelet count (R2 = 0.003: 
P = .78). Mepacrine fluorescence was in perfect agreement (ƙ = 1) with 
platelet ADP content (Figure 2A) and mepacrine release after PAR1-AP 
activation was in good agreement (ƙ = 0.93) with platelet ADP con-
tent (Figure 2B). Mepacrine fluorescence was also in good agreement 
(ƙ = 0.93) with PAR1-AP-induced mepacrine release (Figure 2C).
3.2 | Validation of mepacrine fluorescence in 
patients with suspected platelet function disorders
To prospectively validate mepacrine fluorescence and mepacrine re-
lease in a relevant patient population, we compared these parameters 
with platelet ADP content as the gold standard in the TiN cohort. This 
cohort included 173 patients with a bleeding tendency, in whom a 
platelet function disorder was suspected. Mepacrine fluorescence 
data were not obtained in 17 patients. Consequently, 156 patients 
were used in the current analyses. Based on the 2.5th percentile of 
49 healthy controls, the cutoff for normal platelet ADP content was 
set at 1.4 µmol/1011 platelets. In total, 17 of 156 patients (Table 2) 
had a platelet ADP content below 1.4 µmol/1011 platelets and were 
diagnosed with δ-SPD (Figure 3A). Both mepacrine fluorescence 
(Figure 3B) and mepacrine release (Figure 3C) were decreased in pa-
tients with δ-SPD. Mepacrine fluorescence (Figure 3D; R2 = 0.18) and 
mepacrine release (Figure 3E; R2 = 0.10) correlated with platelet ADP 
content. The discriminative ability of mepacrine fluorescence and 
mepacrine release were determined with the area under a receiver-
operator curve (AUC) (Figure 3F). Mepacrine fluorescence (AUC 0.87; 
95% confidence interval [CI] 0.76-0.96) and mepacrine release (AUC 
TA B L E  1   Baseline characteristics of δ-storage pool disease 
patients
SPD patients n = 7 Reference value
Male 3  
Age (years), median 
(IQR)
48 (23.5-63)  
Platelet count (109/L), 
median (IQR)
232 (183-306) 150-450
MPV (fL), median (IQR) 7.2 (6.8-7.5) 7.0-9.5
Platelet ADP content 
(µmol/1011 platelets), 
median (IQR)
1 (0.5-1.43) 1.7-3.8
Number of dense gran-
ules, median (IQR)
0.85 (0.5-1.15) 4-6
Abbreviations: IQR, interquartile range; MPV, mean platelet volume.
F I G U R E  1   High discriminative ability of flow cytometric 
measurement of platelet-dense granule content in patients with 
previously diagnosed δ-SPD. (A) Platelet ADP content, expressed 
as µmol/1011 platelets measured with luminescence, (B) platelet 
ADP/ATP ratio, (C) normalized mepacrine fluorescence, and (D) 
mepacrine release in 20 healthy controls (closed symbols) and 7 
δ-SPD patients measured with flow cytometry. The dotted line 
represents the 2.5th percentile of the healthy control population. 
*P value < .05
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0.79; 95% CI 0.67-0.91) showed good discriminative ability for diag-
nosing δ-SPD. When a more stringent definition of δ-SPD, based on 
both platelet ADP content < 1.4 µmol/1011 platelets and an ATP/ADP 
ratio > 2, was used, 15 patients met the diagnostic criteria for δ-SPD. 
This did not affect the AUC for mepacrine fluorescence (AUC 0.90, 
95% CI 0.81-0.996, P = .42).
Based on the area under the receiver operating characteristic 
(ROC) curve, the optimal diagnostic cutoff for mepacrine fluores-
cence was 71.2% of normal and 51.3% of normal for mepacrine re-
lease. Based on these cutoff values, the diagnostic accuracy for both 
mepacrine fluorescence and mepacrine release was determined 
(Table 3). With a sensitivity of 76.5% (95% CI 50.1-93.2) and a spec-
ificity of 82.7% (95% CI 75.4-86.6), mepacrine fluorescence showed 
moderate diagnostic accuracy. The diagnostic accuracy for mepa-
crine release was similar. The 2.5th percentile of healthy controls, a 
commonly used cutoff value in clinical laboratories, showed a similar 
diagnostic accuracy for mepacrine fluorescence, but the sensitivity 
of mepacrine release decreased to 35% (P = .02). To evaluate the po-
tential use of mepacrine fluorescence as a screening test for δ-SPD, 
diagnostic accuracy was determined at several cutoff values. At a 
cutoff value below 84.3% of normal, the sensitivity of mepacrine 
fluorescence was 94.1% and specificity was 50.4%. The positive 
likelihood ratio was 1.9, indicating mepacrine fluorescence is a poor 
predictor of δ-SPD, but the negative likelihood ratio was 0.1, indi-
cating that mepacrine fluorescence can be used to exclude δ-SPD.
4  | DISCUSSION
In the present study, we show that patients with δ-SPD have both 
decreased mepacrine uptake and decreased mepacrine release after 
platelet stimulation compared with healthy controls. Because of the 
high negative predictive value (NPV), but low positive predictive 
value, mepacrine fluorescence can be used for exclusion of δ-SPD in 
patients with a suspected platelet function disorder.
Flow cytometry has been recommended by the International 
Society on Thrombosis and Haemostasis/Scientific and 
Standardization Committee guidelines in the diagnostic workup of 
patients with platelet function disorders.9 It has been shown that 
flow cytometry has added value to the current diagnostic workup 
of patients with suspected platelet function disorders, but its value 
in diagnosing δ-SPD in particular has not been validated.19 We are 
F I G U R E  2   Statistically relevant agreement between mepacrine fluorescence and platelet ADP content in diagnostic testing of δ-SPD. 
Cohen's kappa was calculated to determine the agreement between (A) mepacrine fluorescence and platelet ADP content (B) mepacrine 
release and platelet ADP content (C) mepacrine release and mepacrine fluorescence in 20 healthy controls and 7 δ-SPD patients. Platelet 
ADP content is expressed in µmol/1011 platelets. Mepacrine fluorescence and release are normalized on the median fluorescence of the 
healthy control group. The dotted line represents the 2.5th percentile of the healthy control population
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A B C
Mepacrine fluorescence
(nMFI)
 Non-SPD (n = 139) SPD (n = 17) Reference value
Male (%) 22 (16) 7 (41%)  
Age (years), median (IQR) 38 (29-52) 41 (31-56)  
Bleeding score, median 
(IQR)
9 (7-12) 10 (8-14) Male < 4, 
female < 629
Platelet count (109/L), 
median (IQR)
235 (190-282) 200 (69-272) 150-450
MPV (fL), median, (IQR) 8 (7.2-8.7) 7.4 (6.5-8.2) 7.0-9.5
Platelet ADP content 
(µmol/1011 platelets), 
median (IQR)
2.5 (2.1-2.8) 0.9 (0.5-1.2) 1.4-3.8
Abbreviations: IQR, interquartile range; MPV, mean platelet volume.
TA B L E  2   Characteristics of patients 
with a suspected platelet function 
disorder
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the first to prospectively evaluate the diagnostic accuracy of flow 
cytometric mepacrine fluorescence in patients with a suspected 
platelet function disorder. Previous studies already showed that 
mepacrine uptake is decreased in patients with δ-SPD.22,24,25 One 
of these studies compared flow cytometric mepacrine assays with 
routine diagnostic tests in patients with δ-SPD.22 Similar to these 
studies, we found that mepacrine fluorescence allows perfect dis-
crimination between patients with confirmed δ-SPD and healthy 
controls. In contrast to these findings, the performance of mepa-
crine fluorescence was inferior to platelet ADP measurements in 
F I G U R E  3   Diagnostic accuracy of flow cytometric mepacrine uptake and mepacrine release in patients with suspected platelet function 
disorders. (A) Platelet ADP content, expressed as µmol/1011 platelets, (B) mepacrine fluorescence expressed as normalized mean florescence 
intensity, (C) normalized mepacrine release for all patients included in the validation cohort. Patients were classified as bleeding tendency 
(BT) without δ-SPD (BT; n = 139), or patients with a bleeding tendency and δ-SPD (SPD; n = 17). The cutoff value for ADP content was 
1.4 µmol ADP/1011 platelets. The correlation of (D) mepacrine fluorescence and (E) mepacrine release with platelet ADP content in all 156 
patients with suspected platelet function disorder. (F) The discriminative ability of mepacrine fluorescence (area under the curve [AUC] 0.87) 
and mepacrine release (AUC 0.79) with platelet ADP as reference test plotted in a ROC curve. *P value < .05
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TA B L E  3   Diagnostic accuracy of mepacrine fluorescence and mepacrine release at different cutoff values compared with platelet ADP 
content as gold standard
Cutoff (normalized 
median fluorescent 
intensity) Sensitivity Specificity
Positive 
predictive value
Negative 
predictive value Cohen's ĸ
Positive 
likelihood 
ratio
Negative 
likelihood 
ratio
Mepacrine fluorescence
67.8a 70.6 (44.0-89.7) 88.5 (82.0-93.3) 42.9 (30.1-56.6) 96.1 (92.2-98.1) 0.46 6.1 (3.5-10.7) 0.3 (0.2-0.7)
71.2b 76.5 (50.1-93.2) 82.7 (75.4-86.6) 35.1 (25.7-45.9) 96.6 (92.4-98.60) 0.39 4.4 (2.8-6.9) 0.3 (0.1-0.7)
84.3c 94.1 (71.3-99.9) 50.4 (41.8-59.0) 18.8 (15.9-22.2) 98.6 (91.2-99.8) 0.16 1.9 (1.5-2.3) 0.1 (0.02-0.8)
Mepacrine release
43.5a 35.3 (14.2-61.7) 87.8 (81.1-92.7) 26.1 (13.9-43.6) 91.7 (88.6-94.1) 0.20 2.9 (1.3-6.3) 0.7 (0.5-1.1)
51.3b 76.5 (50.1-93.2) 76.3 (68.3-83.1) 28.3 (20.9-37.0) 96.4 (91.8-98.4) 0.30 3.2 (2.2-4.8) 0.3 (0.1-0.7)
aCutoff value derived from the 2.5th percentile of mepacrine fluorescence or release in healthy controls.
bCutoff value derived from the ROC curve.
cOptimal cutoff value as screening test for δ-SPD.
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the prospective evaluation of δ-SPD in unselected patients with 
a bleeding tendency in whom a platelet function disorder was 
suspected.
We evaluated both mepacrine fluorescence in resting platelets 
and mepacrine release after platelet stimulation. Of these two pa-
rameters, mepacrine fluorescence seems more specific, because 
it provides a direct measure of platelet dense granule content 
without the necessity of platelet stimulation. Mepacrine release 
requires platelet stimulation and therefore cannot discriminate 
between impaired platelet activation and a secretion defect, be-
cause both result in decreased mepacrine release. This is reflected 
by the superior diagnostic accuracy of mepacrine fluorescence 
compared with mepacrine release in unselected patients with a 
bleeding tendency, in whom other platelet function disorders are 
common.
The strength of this study is that a selected cohort of patients 
with a suspected platelet function disorder was used for validation 
of mepacrine fluorescence. All tests were performed simultane-
ously and researchers were blinded for the diagnosis; therefore, 
there was no selection bias in this cohort. A potential weakness of 
our study is that we used platelet ADP content as a reference test. 
As a consequence, we could have missed δ-SPD caused by a se-
cretion defect. Moreover, we could have falsely diagnosed δ-SPD 
in patients with a decreased metabolic adenosine nucleotide con-
centration, which is characterized by a low ATP/ADP ratio. This is 
not likely to have influenced the outcome of our study because 
application of a more stringent definition of δ-SPD that includes an 
ATP/ADP ratio > 2 resulted in a similar performance of mepacrine 
fluorescence. Another limitation of this study is that the diagnosis 
of δ-SPD was not confirmed in a second visit to our diagnostic 
center. This may have led to an overestimation of the number of 
patients with SPD in our study.
We report a high NPV for mepacrine fluorescence, which sug-
gests mepacrine fluorescence can be used to exclude δ-SPD. Our 
validation cohort consisted of undiagnosed patients with a bleeding 
tendency in whom a platelet function disorder was suspected and 
therefore reflects the real-life patient population seen at a tertiary 
referral center. As a result, the prevalence of δ-SPD in our study pop-
ulation was relatively high (11%) compared with the expected prev-
alence of δ-SPD in the general population. This might have caused 
an overestimation of the NPV of mepacrine fluorescence. However, 
we also found a low negative likelihood of mepacrine fluorescence 
for δ-SPD (negative likelihood ratio 0.1), which is independent of the 
prevalence and supports the ability of mepacrine fluorescence to 
exclude δ-SPD.
The current diagnostic approach for δ-SPD does not include a 
rapid screening test and could benefit from an additional test such as 
flow cytometry. Unlike the currently available diagnostic tools, flow 
cytometry is applicable in thrombocytopenic samples and requires 
only a small sample volume, allowing rapid exclusion of δ-SPD in 
children.27,28 Our data indicate that flow cytometric analysis is very 
reproducible, even immediately after blood collection.
Taken together, these data indicate that flow cytometric mea-
surement of dense granule parameters is a potential tool for the 
screening of δ-SPD. The presented method requires a minimal 
amount of whole blood and can be used to for the exclusion of 
δ-SPD and for the selection of patients that require further exten-
sive testing.
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